Detail akcie Molecular Partn N online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Molecular Partners AG revenues decreased from SF5M to SF0K. Net loss increased 14% to SF61.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Net foreign exchange loss increase from SF0K to SF5M (expense), Net Foreign Exchange Gain decrease from SF3.8M (income) to SF0K.